PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
22682639-2	2012	IGF-I is an important stimulant of protein synthesis in muscle, but it also stimulates free fatty acid use.	Fatty Acids, Nonesterified	87-102	insulin like growth factor 1	Homo sapiens	0-5	
23512893-0	2013	IGF-I attenuates FFA-induced activation of JNK1 phosphorylation and TNFalpha expression in human subcutaneous preadipocytes.	Fatty Acids, Nonesterified	17-20	insulin like growth factor 1	Homo sapiens	0-5	
23512893-12	2013	CONCLUSIONS: IGF-I attenuated FFA-induced JNK1 phosphorylation and TNFalpha expression through activation of AKT in human subcutaneous but not omental preadipocytes.	Fatty Acids, Nonesterified	30-33	insulin like growth factor 1	Homo sapiens	13-18	
10828823-6	2000	It has been observed that free fatty acids inhibit glucose- and glucose-dependent IGF-I/GH-induced beta-cell proliferation.	Fatty Acids, Nonesterified	26-42	insulin like growth factor 1	Homo sapiens	82-87	
21816784-3	2011	OBJECTIVE: Our objective was to examine the relationship between NAFLD and IGF-I levels and to test the hypothesis that free fatty acids-induced insulin resistance might impair insulin-induced increase of GH receptor (GHR) expression in human hepatoma cells.	Fatty Acids, Nonesterified	120-136	insulin like growth factor 1	Homo sapiens	75-80	
16172212-1	2005	Compelling evidence from epidemiologic studies indicates that elevated circulating insulin-like growth factor (IGF)-I, insulin resistance, and associated complications, such as elevated fasting plasma insulin, glucose and free fatty acids, glucose intolerance, increased body mass index, and visceral adiposity, are linked with increased risk of colorectal cancer.	Fatty Acids, Nonesterified	222-238	insulin like growth factor 1	Homo sapiens	83-117	
7714106-6	1995	Subcutaneous administration of IGF-I (40, 80, and 120 micrograms/kg), although not affecting plasma glucose, resulted in a rapid decrease in free fatty acids and prevented the rise of beta-hydroxybutyrate levels compared to placebo.	Fatty Acids, Nonesterified	141-157	insulin like growth factor 1	Homo sapiens	31-36	
10573439-11	1999	Finally, low plasma IGF-1 concentration predicts a decline in WBGD independent of body fat, free fatty acids, waist/hip ratio, and basal adjusted respiratory quotient (model 3).	Fatty Acids, Nonesterified	92-108	insulin like growth factor 1	Homo sapiens	20-25	
9215295-13	1997	The correlation between the plasma IGF-I/IGFBP-3 molar ratio and WBGD persisted after adjustment for body fat, fasting plasma insulin concentration, daily carbohydrate and fat intake, and daily physical activity (r = 0.55; P < 0.009), but not after further adjustment for plasma free fatty acid concentration (r = 0.30; P = 0.17).	Fatty Acids, Nonesterified	282-297	insulin like growth factor 1	Homo sapiens	35-40	
8928757-3	1996	In the basal state, net forearm uptake of free fatty acids and ketone bodies was increased during IGF-I administration in the face of elevated plasma levels of these substrates, whereas basal glucose levels and forearm glucose balance were unchanged.	Fatty Acids, Nonesterified	42-58	insulin like growth factor 1	Homo sapiens	98-103	
31680542-11	2019	IGF1 also has a direct and indirect glucose-lowering effect, enhances free fatty acid oxidation in the muscle, reducing the flow of free fatty acid into the liver, improving insulin signaling, resulting in the reduction of hepatic glucose output, and improves insulin sensitivity.	Fatty Acids, Nonesterified	70-85	insulin like growth factor 1	Homo sapiens	0-4	
1430077-5	1992	Plasma free fatty acid concentrations decreased during 7.5, 15, and 30 micrograms/kg.h IGF-I by 23%, 34%, and 48%, respectively.	Fatty Acids, Nonesterified	7-22	insulin like growth factor 1	Homo sapiens	87-92	
3127426-8	1988	Concomitantly, fasting resulted in a decline (day 1 vs. day 5) in serum concentrations of somatomedin C (1.31 +/- 0.22 vs. 0.77 +/- 0.18 U/ml) and glucose (4.9 +/- 0.2 vs. 3.2 +/- 0.2 mmol/liter), and a marked rise in free fatty acid (0.43 +/- 0.12 vs. 1.55 +/- 0.35 mmol/liter) and acetoacetate (35 +/- 6 vs. 507 +/- 80 nmol/liter).	Fatty Acids, Nonesterified	218-233	insulin like growth factor 1	Homo sapiens	90-103	
1563078-16	1992	CONCLUSIONS: Patients with Turner"s syndrome who had lower basal IGF-I levels had significantly higher responses of IGF-I, free fatty acids and hydroxyproline (P less than 0.01 for all parameters) after short-term GH application.	Fatty Acids, Nonesterified	123-139	insulin like growth factor 1	Homo sapiens	65-70	
32120345-9	2020	In vitro up-regulation of miR-378a markedly inhibited free fatty acid (FFA)-induced VSMC proliferation, migration and inflammation through targeting IGF1 and TLR8.	Fatty Acids, Nonesterified	54-69	insulin like growth factor 1	Homo sapiens	149-153	
32120345-9	2020	In vitro up-regulation of miR-378a markedly inhibited free fatty acid (FFA)-induced VSMC proliferation, migration and inflammation through targeting IGF1 and TLR8.	Fatty Acids, Nonesterified	71-74	insulin like growth factor 1	Homo sapiens	149-153	
31680542-11	2019	IGF1 also has a direct and indirect glucose-lowering effect, enhances free fatty acid oxidation in the muscle, reducing the flow of free fatty acid into the liver, improving insulin signaling, resulting in the reduction of hepatic glucose output, and improves insulin sensitivity.	Fatty Acids, Nonesterified	132-147	insulin like growth factor 1	Homo sapiens	0-4	
28545881-3	2017	The purpose of this study was to determine the effect of free fatty acids (FFA) present in a high-fat diet on IGF-1 function in cartilage and the role of endoplasmic reticulum (ER) stress.	Fatty Acids, Nonesterified	57-73	insulin like growth factor 1	Homo sapiens	110-115